Y Intercept Hong Kong Ltd Purchases 20,279 Shares of Stryker Corporation $SYK

Y Intercept Hong Kong Ltd boosted its position in shares of Stryker Corporation (NYSE:SYK) by 229.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,135 shares of the medical technology company’s stock after acquiring an additional 20,279 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Stryker were worth $10,240,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Godfrey Financial Associates Inc. bought a new position in shares of Stryker in the fourth quarter valued at about $26,000. United Financial Planning Group LLC bought a new position in shares of Stryker in the third quarter valued at about $27,000. DJE Kapital AG bought a new position in shares of Stryker in the fourth quarter valued at about $28,000. Strive Asset Management LLC bought a new position in shares of Stryker in the third quarter valued at about $30,000. Finally, CGC Financial Services LLC bought a new position in shares of Stryker in the fourth quarter valued at about $29,000. 77.09% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

SYK has been the topic of several research analyst reports. Wall Street Zen lowered shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Canaccord Genuity Group dropped their price objective on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. JPMorgan Chase & Co. dropped their price objective on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Wells Fargo & Company dropped their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Finally, Weiss Ratings lowered shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus price target of $395.33.

Stryker Price Performance

NYSE:SYK opened at $312.14 on Friday. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The firm has a market cap of $119.66 billion, a price-to-earnings ratio of 36.13, a P/E/G ratio of 1.93 and a beta of 0.78. The firm’s 50-day simple moving average is $316.40 and its 200 day simple moving average is $343.97. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same period in the prior year, the business posted $2.84 earnings per share. Stryker’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, sell-side analysts predict that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is presently 40.74%.

Insiders Place Their Bets

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 323,264 shares of company stock worth $100,659,489 over the last ninety days. Corporate insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.